This article is more than 5 years old. Information may no longer be current.

VIDEO: Barriers, legal hurdles, limitations of anti-VEGF treatment in France

Issue: May 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — At the meeting of the French Society of Ophthalmology, Laurent Kodjikian, MD, PhD, talks about Temporary Authorization for Use of Genentech's Avastin bevacizumab injection for the treatment of wet age-related macular degeneration in France, and the barriers, legal hurdles and limitations that prevent doctors from taking advantage of this new opportunity.